197 related articles for article (PubMed ID: 10975474)
1. Plasma exchange for treatment of myasthenia gravis: pathophysiologic basis and clinical experience.
Qureshi AI; Suri MF
Ther Apher; 2000 Aug; 4(4):280-6. PubMed ID: 10975474
[TBL] [Abstract][Full Text] [Related]
2. [Contribution of intravenous immunoglobulins to the treatment of myasthenia].
Gajdos P
Ann Med Interne (Paris); 2000 May; 151 Suppl 1():1S30-4. PubMed ID: 10896986
[TBL] [Abstract][Full Text] [Related]
3. Intravenous immune globulin in myasthenia gravis.
Gajdos P
Clin Exp Immunol; 1994 Jul; 97 Suppl 1(Suppl 1):49-51. PubMed ID: 8033435
[TBL] [Abstract][Full Text] [Related]
4. Pediatric Myasthenia Gravis.
Peragallo JH
Semin Pediatr Neurol; 2017 May; 24(2):116-121. PubMed ID: 28941526
[TBL] [Abstract][Full Text] [Related]
5. Therapy in myasthenia gravis and Lambert-Eaton myasthenic syndrome.
Newsom-Davis J
Semin Neurol; 2003 Jun; 23(2):191-8. PubMed ID: 12894384
[TBL] [Abstract][Full Text] [Related]
6. Management of myasthenia gravis.
Schwendimann RN; Burton E; Minagar A
Am J Ther; 2005; 12(3):262-8. PubMed ID: 15891271
[TBL] [Abstract][Full Text] [Related]
7. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis.
Evoli A; Tonali PA; Padua L; Monaco ML; Scuderi F; Batocchi AP; Marino M; Bartoccioni E
Brain; 2003 Oct; 126(Pt 10):2304-11. PubMed ID: 12821509
[TBL] [Abstract][Full Text] [Related]
8. Myasthenia and the neuromuscular junction.
Gilhus NE
Curr Opin Neurol; 2012 Oct; 25(5):523-9. PubMed ID: 22892950
[TBL] [Abstract][Full Text] [Related]
9. The immune system, Part 2: Myasthenia gravis.
Stephens A
Nurs Times; 1997 Nov 12-18; 93(46):56-9. PubMed ID: 9418490
[No Abstract] [Full Text] [Related]
10. Myasthenia gravis crisis.
Bershad EM; Feen ES; Suarez JI
South Med J; 2008 Jan; 101(1):63-9. PubMed ID: 18176295
[TBL] [Abstract][Full Text] [Related]
11. Myasthenia gravis: emerging new therapy options.
Sieb JP
Curr Opin Pharmacol; 2005 Jun; 5(3):303-7. PubMed ID: 15907918
[TBL] [Abstract][Full Text] [Related]
12. Predictable recovery from myasthenia gravis crisis with plasma exchange: thirty-six cases and review of current management.
Mahalati K; Dawson RB; Collins JO; Mayer RF
J Clin Apher; 1999; 14(1):1-8. PubMed ID: 10355656
[TBL] [Abstract][Full Text] [Related]
13. New treatment approaches to myasthenia gravis.
Havard CW; Fonseca V
Drugs; 1990 Jan; 39(1):66-73. PubMed ID: 2178913
[TBL] [Abstract][Full Text] [Related]
14. Plasma exchange for myasthenia gravis.
Gajdos P; Chevret S; Toyka K
Cochrane Database Syst Rev; 2002; 2002(4):CD002275. PubMed ID: 12519572
[TBL] [Abstract][Full Text] [Related]
15. Comparative effects of plasma exchange and pyridostigmine on respiratory muscle strength and breathing pattern in patients with myasthenia gravis.
Goti P; Spinelli A; Marconi G; Duranti R; Gigliotti F; Pizzi A; Scano G
Thorax; 1995 Oct; 50(10):1080-6. PubMed ID: 7491557
[TBL] [Abstract][Full Text] [Related]
16. Intravenous immunoglobulin for myasthenia gravis.
Gajdos P; Chevret S; Toyka K
Cochrane Database Syst Rev; 2003; (2):CD002277. PubMed ID: 12804431
[TBL] [Abstract][Full Text] [Related]
17. Myasthenia gravis: immunological mechanisms and immunotherapy.
Lewis RA; Selwa JF; Lisak RP
Ann Neurol; 1995 May; 37 Suppl 1():S51-62. PubMed ID: 8968217
[TBL] [Abstract][Full Text] [Related]
18. Intravenous immunoglobulin for the treatment of acquired myasthenia gravis.
Howard JF
Neurology; 1998 Dec; 51(6 Suppl 5):S30-6. PubMed ID: 9851728
[TBL] [Abstract][Full Text] [Related]
19. [Myasthenia gravis].
Müllges W; Stoll G
Nervenarzt; 2019 Oct; 90(10):1055-1066. PubMed ID: 31538208
[TBL] [Abstract][Full Text] [Related]
20. A comparison of the effectiveness of intravenous immunoglobulin and plasma exchange as preoperative therapy of myasthenia gravis.
Jensen P; Bril V
J Clin Neuromuscul Dis; 2008 Mar; 9(3):352-5. PubMed ID: 18344718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
